AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Allogene Therapeutics Maintains Buy Rating Amid Strategic Adjustments and Technological Advancements
ByAinvest
Monday, Aug 4, 2025 8:21 pm ET1min read
Analyst John Newman maintains a Buy rating for Allogene Therapeutics with a $14 price target, citing the company's strategic decisions and technological advancements. The decision to drop the FCA lymphodepletion regimen in their ALPHA3 study and the innovative dagger technology are seen as promising long-term solutions for improving efficacy and safety in allogeneic CAR-T therapies. Newman has an average return of -4.6% and a 34.75% success rate in the Healthcare sector.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet